Literature DB >> 9095165

Multidrug resistance--a multiplex phenomenon.

N Baldini.   

Abstract

Mesh：

Substances：

Year:  1997        PMID： 9095165     DOI： 10.1038/nm0497-378

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  7 in total

1.  A water soluble parthenolide analog suppresses in vivo tumor growth of two tobacco-associated cancers, lung and bladder cancer, by targeting NF-κB and generating reactive oxygen species.

Authors:  Rajasubramaniam Shanmugam; Praveen Kusumanchi; Hitesh Appaiah; Liang Cheng; Peter Crooks; Sundar Neelakantan; Tyler Peat; James Klaunig; William Matthews; Harikrishna Nakshatri; Christopher J Sweeney
Journal:  Int J Cancer       Date:  2011-05-15       Impact factor: 7.396

2.  Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer.

Authors:  Eardie A Curry; Daryl J Murry; Christy Yoder; Karen Fife; Victoria Armstrong; Harikrishna Nakshatri; Michael O'Connell; Christopher J Sweeney
Journal:  Invest New Drugs       Date:  2004-08       Impact factor: 3.850

3.  Deficient activation of CD95 (APO-1/Fas)-mediated apoptosis: a potential factor of multidrug resistance in human renal cell carcinoma.

Authors:  U Ramp; M Dejosez; C Mahotka; B Czarnotta; T Kalinski; M Wenzel; I Lorenz; M Müller; P Krammer; H E Gabbert; C D Gerharz
Journal:  Br J Cancer       Date:  2000-06       Impact factor: 7.640

4.  The nuclear-cytoplasmic trafficking of a chromatin-modifying and remodelling protein (KMT2C), in osteosarcoma.

Authors:  Caterina Chiappetta; Chiara Puggioni; Raffaella Carletti; Vincenzo Petrozza; Carlo Della Rocca; Claudio Di Crisfofano
Journal:  Oncotarget       Date:  2018-07-17

Review 5.  Sarcoma treatment in the era of molecular medicine.

Authors:  Thomas Gp Grünewald; Marta Alonso; Sofia Avnet; Ana Banito; Stefan Burdach; Florencia Cidre-Aranaz; Gemma Di Pompo; Martin Distel; Heathcliff Dorado-Garcia; Javier Garcia-Castro; Laura González-González; Agamemnon E Grigoriadis; Merve Kasan; Christian Koelsche; Manuela Krumbholz; Fernando Lecanda; Silvia Lemma; Dario L Longo; Claudia Madrigal-Esquivel; Álvaro Morales-Molina; Julian Musa; Shunya Ohmura; Benjamin Ory; Miguel Pereira-Silva; Francesca Perut; Rene Rodriguez; Carolin Seeling; Nada Al Shaaili; Shabnam Shaabani; Kristina Shiavone; Snehadri Sinha; Eleni M Tomazou; Marcel Trautmann; Maria Vela; Yvonne Mh Versleijen-Jonkers; Julia Visgauss; Marta Zalacain; Sebastian J Schober; Andrej Lissat; William R English; Nicola Baldini; Dominique Heymann
Journal:  EMBO Mol Med       Date:  2020-10-13       Impact factor: 12.137

6.  Whole-exome analysis in osteosarcoma to identify a personalized therapy.

Authors:  Chiara M Mazzanti; Claudio Di Cristofano; Caterina Chiappetta; Massimiliano Mancini; Francesca Lessi; Paolo Aretini; Veronica De Gregorio; Chiara Puggioni; Raffaella Carletti; Vincenzo Petrozza; Prospero Civita; Sara Franceschi; Antonio G Naccarato; Carlo Della Rocca
Journal:  Oncotarget       Date:  2017-07-05

7.  Altered pH gradient at the plasma membrane of osteosarcoma cells is a key mechanism of drug resistance.

Authors:  Sofia Avnet; Silvia Lemma; Margherita Cortini; Paola Pellegrini; Francesca Perut; Nicoletta Zini; Katsuyuki Kusuzaki; Tokuhiro Chano; Giulia Grisendi; Massimo Dominici; Angelo De Milito; Nicola Baldini
Journal:  Oncotarget       Date:  2016-09-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.